From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857, USA.
D000077284:Abciximab; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D017130:Angioplasty / Q000009:adverse effects / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use*; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D004366:Nonprescription Drugs / Q000592:standards*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013089:Spermatocidal Agents / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D015507:Drugs, Investigational; D007140:Immunoglobulin Fab Fragments; D004366:Nonprescription Drugs; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D013089:Spermatocidal Agents; D003841:Deoxycytidine; D013006:Growth Hormone; D000077284:Abciximab; D000093542:Gemcitabine